Skip to main
EVH
EVH logo

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health Inc. is well-positioned for significant growth due to its ability to expand service offerings and secure valuable contracts, with expectations of the Aetna contract potentially generating over $2 billion in annual revenue. The company maintains a strong revenue growth trajectory, surpassing its mid-teens growth target, bolstered by a robust pipeline and a record momentum for new contracts, which indicates continued demand for its specialty-focused value-based care services. Additionally, Evolent's contracts now include adaptive pricing mechanisms linked to disease prevalence, reinforcing its financial sustainability and alignment with ongoing market trends favoring value-based payment models.

Bears say

Evolent Health Inc is facing significant revenue challenges, with projections indicating a substantial decline in non-enhanced revenue from approximately $285 million in 2025 to about $170 million in 2026 due to shifts in their service mix. Additionally, the company anticipates a decrease in membership across key programs, with potential declines in Exchange membership leading to expected EBITDA reductions in the range of $134 to $144 million, factoring in only limited benefits from AI-related efficiency initiatives. Lastly, declines in higher-margin Exchange enrollment and a projected 5% decrease in Medicaid membership could further negatively impact EBITDA by approximately $8 million to $15 million, raising concerns about the company's overall financial stability moving forward.

Evolent Health (EVH) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 15 analysts, Evolent Health (EVH) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.